Achilles Therapeutics plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Achilles Therapeutics plc is a biopharmaceutical company that has historically pursued the development of precision T-cell therapies for various solid tumors. The company's strategy centered on its unique PELEUS artificial intelligence platform, designed to identify clonal neoantigens, which are distinct protein markers present on all cancer cells but absent from healthy tissue. These neoantigens were the target for their earlier therapeutic candidates. Recently, Achilles Therapeutics announced a significant strategic shift, discontinuing its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T-cell (cNeT) therapy program. This decision led to the closure of its Phase I/IIa clinical trials, CHIRON for advanced non-small cell lung cancer and THETIS for metastatic or recurrent melanoma. The company is now exploring strategic options and potential collaborations with other entities to leverage its core capabilities in identifying clonal neoantigens for alternative therapeutic approaches, such as neoantigen vaccines, antibody-drug conjugates, and T-cell receptor therapies. In line with this refocus, Achilles Therapeutics has initiated a voluntary delisting from Nasdaq and plans to seek shareholder approval for a members' voluntary liquidation by March 2025. The company was founded in 2016 and is headquartered in London, United Kingdom.
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
Achilles Therapeutics Announces Strategic Update
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics to Present at Upcoming Conferences
3 Stocks With 1,000% Upside Potential
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?